Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | CHRNB2 | P17787 | 6/20 | 0.34 |
| ▸ | CHRNB4 | P30926 | 6/20 | 0.34 |
| ▸ | CHRNA3 | P32297 | 6/20 | 0.34 |
| ▸ | CHRNA4 | P43681 | 6/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6626133 | 0.94 | CHRNB2 (0.36) | L3MBTL3L3MBTL1CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL3573719 | 0.93 | CHRNB2 (0.37) | CHRNB2CHRNB4CHRNA3CHRNA4HRH3 | |
| SCHEMBL5832776 | 0.83 | CHRNB2 (0.51) | CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL5832150 | 0.83 | CHRNB2 (0.48) | L3MBTL3L3MBTL1CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL6626078 | 0.83 | DPP4 (0.42) | L3MBTL3L3MBTL1CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL5832239 | 0.79 | CHRNA7 (0.57) | CHRNB2CHRNA4HRH3 | |
| SCHEMBL6624541 | 0.78 | OGA (0.37) | CHRNB2CHRNB4CHRNA3CHRNA4HRH3 | |
| SCHEMBL5832405 | 0.77 | CHRNB2 (0.49) | CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL6625195 | 0.77 | DPP4 (0.44) | CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL5041409 | 0.77 | CHRNB2 (0.53) | CHRNB2CHRNB4CHRNA3CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1177196-B1 | HETEROARYL DIAZABICYCLOALKANES, THEIR PREPARATION AND USE | NEUROSEARCH AS (DK) | 2004-03-10 | — | — | EP | claimed |
| US-6552012-B2 | 3-(6-Chloro-(3-pyridazinyl))-9-methyl-3,9-diazabicyclo(4.2.1)-nonane, for example; Alzheimer's disease, Parkinson's disease, memory dysfunction, smoking cessation, drug abuse, drug dependence; cholinergic ligands | NEUROSEARCH A/S (DK) | 2003-04-22 | — | — | US | claimed |
| JP-2002543201-A | — | — | 2002-12-17 | — | — | JP | claimed |
| CN-1349533-A | Heteroaryl diazabicycloalkanes, their preparation and use | NEUROSEARCH AS (DK) | 2002-05-15 | — | — | CN | claimed |
| US-20020037893-A1 | Heteroaryl diazabicycloalkanes, their preparation and use | ANIONA APS (DK) | 2002-03-28 | — | — | US | claimed |
| EP-1177196-A1 | HETEROARYL DIAZABICYCLOALKANES, THEIR PREPARATION AND USE | NEUROSEARCH A/S (DK) | 2002-02-06 | — | — | EP | claimed |
| WO-2000066586-A1 | HETEROARYL DIAZABICYCLOALKANES, THEIR PREPARATION AND USE | NEUROSEARCH A/S (DK) | 2000-11-09 | — | — | WO | claimed |
| CN-1210277-C | Heteroaryl diazabicycloalkanes, their prepn. and use | NEUROSEARCH AS (DK) | 2005-07-13 | — | — | CN | disclosed |
| EP-1177196-B1 | HETEROARYL DIAZABICYCLOALKANES, THEIR PREPARATION AND USE | NEUROSEARCH AS (DK) | 2004-03-10 | — | — | EP | disclosed |
| US-6552012-B2 | 3-(6-Chloro-(3-pyridazinyl))-9-methyl-3,9-diazabicyclo(4.2.1)-nonane, for example; Alzheimer's disease, Parkinson's disease, memory dysfunction, smoking cessation, drug abuse, drug dependence; cholinergic ligands | NEUROSEARCH A/S (DK) | 2003-04-22 | — | — | US | disclosed |
| EP-1218342-A2 | MONO- AND BIS-INDOLYLQUINONES AND PROPHYLACTIC AND THERAPEUTIC USES THEREOF | Sugen, Inc. (US) | 2002-07-03 | — | — | EP | disclosed |
| CN-1349533-A | Heteroaryl diazabicycloalkanes, their preparation and use | NEUROSEARCH AS (DK) | 2002-05-15 | — | — | CN | disclosed |
| US-20020037893-A1 | Heteroaryl diazabicycloalkanes, their preparation and use | ANIONA APS (DK) | 2002-03-28 | — | — | US | disclosed |
| EP-1177196-A1 | HETEROARYL DIAZABICYCLOALKANES, THEIR PREPARATION AND USE | NEUROSEARCH A/S (DK) | 2002-02-06 | — | — | EP | disclosed |
| WO-2001021589-A2 | MONO- AND BIS-INDOLYLQUINONES AND PROPHYLACTIC AND THERAPEUTIC USES THEREOF | SUGEN, INC. (US) | 2001-03-29 | — | — | WO | disclosed |
| WO-2000066586-A1 | HETEROARYL DIAZABICYCLOALKANES, THEIR PREPARATION AND USE | NEUROSEARCH A/S (DK) | 2000-11-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020037893-A1 | Heteroaryl diazabicycloalkanes, their preparation and use | CHRNA5, CHRNA7, CHRNA2 | L3MBTL3 4213/4885L3MBTL1 4092/4885CHRNB2 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.